OTC NSAIDs Need Additional Label Warnings – FDA Advisory Panel
This article was originally published in The Tan Sheet
Executive Summary
Labels for OTC NSAIDS need additional information about potential risks, say panel members in a joint meeting of the Arthritis and the Drug Safety and Risk Management advisory committees. Data do not show naproxen has a lower CV thrombotic event risk compared to other NSAIDs, they say.
You may also be interested in...
NSAID Panel Could Give Naproxen Labeling Edge
FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.